MedPath

In vivo REsponse evaluation of colorectal liver metastases during systemic therapy using optical SPECTroscopy techniques

Conditions
unresectable colorectal liver metastases
Registration Number
NL-OMON22669
Lead Sponsor
Philips Research
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
22
Inclusion Criteria

1. Patients with unresectable colorectal liver metastases;

2. The liver lesions are safely accessible according to an intervention-radiologist;

Exclusion Criteria

1. Patients with suspected sensitivity to light; e.g. patients who have had photodynamic therapy;

2. Patients with bleeding disorders (such as hemophilia) or bleeding complications from biopsies, dental procedures or surgery;

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The aim of this pilot study is to investigate whether chemotherapy response can be detected with optical spectroscopy (diffuse reflectance and fluorescence spectroscopy) in patients with unresectable colorectal liver metastases receiving first line systemic therapy.<br>
Secondary Outcome Measures
NameTimeMethod
1.To compare the accuracy of chemotherapy response using optical spectroscopy with standardized RECIST criteria;<br /><br>2.To correlate spectroscopic measurements with tissue characteristics from biopsies;<br /><br>3.During the measurement procedure, possible improvements to the measurement hardware will be recorded which can provide information for possible alterations of hardware design for improved clinical applicability in the future.
© Copyright 2025. All Rights Reserved by MedPath